Hepatitis B Core Antibody, IgM
| Order Code: | HBCM |
| Order Form: | Laboratory Requisition |
Specimen:
Plasma
Collection Medium:
![]() |
| Plasma Separator Tube |
Alternate
Collection Media:
Call laboratory for additional acceptable specimen collection containers.
Minimum:
3 mL whole blood from light green top tube or TWO microtainers for
pediatric patients
Testing
Schedule:
24 hrs/day, 7 days a week, including holidays.
Analytic Time:
1 hour (upon receipt in laboratory)
Reference Range:
See Interpretive Data
Interpretive Data:
< 0.80 — Non-reactive. IgM anti-HBc not detected. Does not
exclude the possibility of exposure to or infection with hepatitis B
virus.
0.80 to < 1.21. Grayzone. Antibodies to IgM anti-HBc may or may not be present. Patients with specimens exhibiting grayzone test results should be retested at approximately one week intervals.
Greater than or equal to 1.21. Reactive. Presumptive evidence of IgM anti-HBc.
0.80 to < 1.21. Grayzone. Antibodies to IgM anti-HBc may or may not be present. Patients with specimens exhibiting grayzone test results should be retested at approximately one week intervals.
Greater than or equal to 1.21. Reactive. Presumptive evidence of IgM anti-HBc.
Comments:
Current methods for the detection of IgM anti-HBc may not detect all
infected individuals. A nonreactive test result does not exclude the
possibility of exposure to or infection with HBV.
The assay is limited to the detection of IgM anti-HBc in human serum or plasma. It can be used to determine whether a patient has, or has recently had, acute or subclinical hepatitis B infection. Supportive clinical information, including other hepatitis B markers, should also be evaluated. The test cannot determine a patient's immune status to hepatitis B.
Specimens from patients with high levels of IgM (e.g., specimens from patients with multiple myeloma) may show depressed values.
The assay is limited to the detection of IgM anti-HBc in human serum or plasma. It can be used to determine whether a patient has, or has recently had, acute or subclinical hepatitis B infection. Supportive clinical information, including other hepatitis B markers, should also be evaluated. The test cannot determine a patient's immune status to hepatitis B.
Specimens from patients with high levels of IgM (e.g., specimens from patients with multiple myeloma) may show depressed values.
Methodology:
Chemiluminescent microparticle immunoassay (CMIA)
Sample
Processing:
Centrifuge at 3000 RPM for 10 minutes.
Aliquot plasma into labeled container and cap.
Label transport tube with two patient identifiers, date and time of collection.
Aliquot plasma into labeled container and cap.
Label transport tube with two patient identifiers, date and time of collection.
Sample
Storage:
Refrigerate.
Transport
Instructions:
Place requisition into outside pocket of bag.
Place specimen into zip-lock type bag, seal bag.
Transport in cooler with refrigerated coolant packs.
Place specimen into zip-lock type bag, seal bag.
Transport in cooler with refrigerated coolant packs.
CPT Code:
86705
